SDS-Page
(Figure 1. SDS-PAGE gel imageThe purity of nCoV-RBD (K417N, E484K, N501Y) was determined to be >90% by densitometry, approx. MW 39 kDa.)
COVID 19 Spike protein RBD (K417N, E484K, N501Y) Coronavirus Active Protein | COVID-19 active protein
2019-nCoV Spike protein RBD (K417N, E484K, N501Y)
Purity
>90%
Synonyms
COVID 19 Spike protein RBD (K417N; E484K; N501Y) Coronavirus; 2019-nCoV Spike protein RBD (K417N; N501Y); 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike protein RBD (K417N; COVID-19 active protein
Host
CHO Cells
Purity/Purification
>90%
Form/Format
Recombinant protein stored in 50mM sodium phosphate, pH 7.5, 300mM NaCl, 150mM imidazole.
Concentration
1.0 ug/ul (varies by lot)
Preparation and Storage
Store product at –70 degree C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
SDS-Page
(Figure 1. SDS-PAGE gel imageThe purity of nCoV-RBD (K417N, E484K, N501Y) was determined to be >90% by densitometry, approx. MW 39 kDa.)
SDS-Page
(Figure 1. SDS-PAGE gel imageThe purity of nCoV-RBD (K417N, E484K, N501Y) was determined to be >90% by densitometry, approx. MW 39 kDa.)
Activity
(Figure 2. Binding ability measured in a functional ELISA. 2019-nCoV spike protein RBD (K417N, E484K, N501Y) binds to immobilized human ACE2 (19-740) protein)
Activity
(Figure 2. Binding ability measured in a functional ELISA. 2019-nCoV spike protein RBD (K417N, E484K, N501Y) binds to immobilized human ACE2 (19-740) protein)
Related Product Information for COVID-19 active protein
Recombinant viral protein expressed in CHO cells.
Recombinant 2019-nCoV Spike protein S1 subunit, RBD (K417N, E484K, N501Y) (319-541) was expressed in CHO cells using a C-terminal his tag. The gene accession number is MN908947.
The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein recognizes the host ACE2 receptor and is a major determinant of viral entry and neutralization (1). SARS-CoV-2 (501Y.V2 variant) with mutations at the key sites in RBD (K417N, E484K and N501Y) has severely affected regions of South Africa (2). MD simulation indicates that the combination of E484K, K417N and N501Y results in the highest degree of conformational modifications of RBD when bound to hACE2, compared to either E484K or N501Y alone. E484K and N501Y increase affinity of RBD for hACE2 and the charge switch due to E484K leads to the formation of favorable contacts. As new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization (3).
Recombinant 2019-nCoV Spike protein S1 subunit, RBD (K417N, E484K, N501Y) (319-541) was expressed in CHO cells using a C-terminal his tag. The gene accession number is MN908947.
The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein recognizes the host ACE2 receptor and is a major determinant of viral entry and neutralization (1). SARS-CoV-2 (501Y.V2 variant) with mutations at the key sites in RBD (K417N, E484K and N501Y) has severely affected regions of South Africa (2). MD simulation indicates that the combination of E484K, K417N and N501Y results in the highest degree of conformational modifications of RBD when bound to hACE2, compared to either E484K or N501Y alone. E484K and N501Y increase affinity of RBD for hACE2 and the charge switch due to E484K leads to the formation of favorable contacts. As new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization (3).
References
1. Lan J, et al: Crystal structure of the 2019-nCov spike receptor-binding domain bound with the ACE2 receptor. bioRxiv.
2.Houriiyah T, et al: Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv 2020
3.Starr TN, et al: Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. Cell. 2020, 182(5):1295-1310.
2.Houriiyah T, et al: Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv 2020
3.Starr TN, et al: Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. Cell. 2020, 182(5):1295-1310.
Similar Products
Product Notes
The COVID-19 (Catalog #AAA515785) is an Active Protein produced from CHO Cells and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "COVID 19 Spike protein RBD (K417N, E484K, N501Y) Coronavirus, Active Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
